File Download
  Links for fulltext
     (May Require Subscription)
  • Find via Find It@HKUL
Supplementary

Conference Paper: 1α, 25-dihydroxyvitamin D3 suppresses differentiation, maturation and activation of dendritic cells from patients with systemic lupus erythematosus

Title1α, 25-dihydroxyvitamin D3 suppresses differentiation, maturation and activation of dendritic cells from patients with systemic lupus erythematosus
Authors
KeywordsMedical sciences
Issue Date2010
PublisherHong Kong Academy of Medicine Press. The Journal's web site is located at http://www.hkmj.org.hk
Citation
The 15th Medical Research Conference (15th MRC), Department of Medicine, University of Hong Kong, Hong Kong, 16 January 2010. In Hong Kong Medical Journal, 2010, v. 16 n. 1, suppl. 1, p. 57, abstract no. 98 How to Cite?
AbstractBACKGROUND: Dendritic cells (DC), professional antigen presenting cells, are believed to play a crucial role in the pathogenesis of systemic lupus erythematosus (SLE). 1α, 25-dihydroxyvitamin D3 (VitD3), in addition to its effect on bone metabolism, has been increasingly recognised to have immunomodulatory effects. OBJECTIVE: To examine the effect of VitD3 on the differentiation, maturation, and activation of DCs in SLE patients. METHODS: CD14+ monocyte–derived DCs from SLE patients and age- and sex-matched controls were derived from growth medium cultured with IL-4, GM-CSF. Mature DCs were induced by addition of lipopolysaccharide and tumour necrosis factor-α in the presence or absence of VitD3 (1×10-10 M) and/or dexamethasone (1×10-6 M). The expression of CD1a, a DC marker and markers of maturation and co-stimulatory molecules such as CD80, CD86, CD40, HLA-DR and CD83 were examined by flow cytometry. After stimulation of DCs with CD40L for 24 hours, the production of pro-inflammatory cytokines including IL-12 and IL-6, were measured by ELISA kits. RESULTS: VitD3 suppresses differentiation of monocytes into DCs as showed by the decreased expression of CD1a (P<0.05). VitD3 inhibits the expression of maturation markers including CD86, CD40 and CD83 (P<0.05), but not CD80 and HLA-DR. This effect was more marked in SLE patients (n=14) than controls (n=9). In combination with dexamethasone, VitD3 displayed more potent immunosuppressive effect on DCs. Under the effect of VitD3, stimulated DCs produced less of IL-12 (3.1 vs 10.4 pg/mL, P=0.02) and IL-6 (216.0 vs 224.0 pg/mL, P=0.21) in SLE patients as well as controls (8.0 vs 36.6 μg/mL, P=0.01 for IL-12) and (380.7 vs 415.2 pg/mL, P=0.04 for IL-6). CONCLUSION: VitD3 is found to inhibit differentiation, maturation, and activation of DCs in vitro in both SLE patients and controls and may be considered as immunomodulatory agent in the treatment of SLE.
Persistent Identifierhttp://hdl.handle.net/10722/129829
ISSN
2015 Impact Factor: 0.887
2015 SCImago Journal Rankings: 0.279

 

DC FieldValueLanguage
dc.contributor.authorWu, Hen_US
dc.contributor.authorChan, WKen_US
dc.contributor.authorMok, MYen_US
dc.contributor.authorWu, XY-
dc.date.accessioned2010-12-23T08:42:43Z-
dc.date.available2010-12-23T08:42:43Z-
dc.date.issued2010en_US
dc.identifier.citationThe 15th Medical Research Conference (15th MRC), Department of Medicine, University of Hong Kong, Hong Kong, 16 January 2010. In Hong Kong Medical Journal, 2010, v. 16 n. 1, suppl. 1, p. 57, abstract no. 98en_US
dc.identifier.issn1024-2708-
dc.identifier.urihttp://hdl.handle.net/10722/129829-
dc.description.abstractBACKGROUND: Dendritic cells (DC), professional antigen presenting cells, are believed to play a crucial role in the pathogenesis of systemic lupus erythematosus (SLE). 1α, 25-dihydroxyvitamin D3 (VitD3), in addition to its effect on bone metabolism, has been increasingly recognised to have immunomodulatory effects. OBJECTIVE: To examine the effect of VitD3 on the differentiation, maturation, and activation of DCs in SLE patients. METHODS: CD14+ monocyte–derived DCs from SLE patients and age- and sex-matched controls were derived from growth medium cultured with IL-4, GM-CSF. Mature DCs were induced by addition of lipopolysaccharide and tumour necrosis factor-α in the presence or absence of VitD3 (1×10-10 M) and/or dexamethasone (1×10-6 M). The expression of CD1a, a DC marker and markers of maturation and co-stimulatory molecules such as CD80, CD86, CD40, HLA-DR and CD83 were examined by flow cytometry. After stimulation of DCs with CD40L for 24 hours, the production of pro-inflammatory cytokines including IL-12 and IL-6, were measured by ELISA kits. RESULTS: VitD3 suppresses differentiation of monocytes into DCs as showed by the decreased expression of CD1a (P<0.05). VitD3 inhibits the expression of maturation markers including CD86, CD40 and CD83 (P<0.05), but not CD80 and HLA-DR. This effect was more marked in SLE patients (n=14) than controls (n=9). In combination with dexamethasone, VitD3 displayed more potent immunosuppressive effect on DCs. Under the effect of VitD3, stimulated DCs produced less of IL-12 (3.1 vs 10.4 pg/mL, P=0.02) and IL-6 (216.0 vs 224.0 pg/mL, P=0.21) in SLE patients as well as controls (8.0 vs 36.6 μg/mL, P=0.01 for IL-12) and (380.7 vs 415.2 pg/mL, P=0.04 for IL-6). CONCLUSION: VitD3 is found to inhibit differentiation, maturation, and activation of DCs in vitro in both SLE patients and controls and may be considered as immunomodulatory agent in the treatment of SLE.-
dc.languageengen_US
dc.publisherHong Kong Academy of Medicine Press. The Journal's web site is located at http://www.hkmj.org.hk-
dc.relation.ispartofHong Kong Medical Journalen_US
dc.rightsHong Kong Medical Journal. Copyright © Hong Kong Academy of Medicine Press.-
dc.rightsCreative Commons: Attribution 3.0 Hong Kong License-
dc.subjectMedical sciences-
dc.title1α, 25-dihydroxyvitamin D3 suppresses differentiation, maturation and activation of dendritic cells from patients with systemic lupus erythematosusen_US
dc.typeConference_Paperen_US
dc.identifier.emailWu, H: chris10@hku.hken_US
dc.identifier.emailChan, WK: wkchanf@hku.hken_US
dc.identifier.emailMok, MY: temy@hkucc.hku.hken_US
dc.identifier.authorityMok, MY=rp00490en_US
dc.description.naturepublished_or_final_version-
dc.identifier.hkuros177407en_US
dc.identifier.volume16en_US
dc.identifier.issue1, suppl. 1-
dc.identifier.spage57en_US
dc.identifier.epage57-
dc.publisher.placeHong Kong-
dc.description.otherThe 15th Medical Research Conference (15th MRC), Department of Medicine, University of Hong Kong, Hong Kong, 16 January 2010. In Hong Kong Medical Journal, 2010, v. 16 n. 1, suppl. 1, p. 57, abstract no. 98-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats